ANGPTL3 and familial hyperaldosteronism: The in vitro design of our study limits the extrapolation of our conclusions to FH patients; however, the mechanisms proposed here are in line with data obtained in animal studies (12, 17) and the clinical observations in FH patients treated with ANGPTL3 inhibitors (5).